RHHBY - Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients | Benzinga
On Thursday, Roche Holdings AG (OTC:RHHBY) said that the Phase 2/3 SKYSCRAPER-06 study of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as first-line treatment for locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis.
The hazard ratio (HR) was 1.27, and overall survival (OS) at its first interim analysis, with an HR of 1.33, was immature.
Merck & Co Inc (NYSE:MRK) markets pembrolizumab as Keytruda.
Also Read: Roche ...